

Kevin Palka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9840940/publications.pdf>

Version: 2024-02-01

7
papers

130
citations

1684188

5
h-index

2053705

5
g-index

7
all docs

7
docs citations

7
times ranked

336
citing authors

#	ARTICLE	IF	CITATIONS
1	nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. <i>Medical Oncology</i> , 2021, 38, 35.	2.5	11
2	Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. <i>Oral Oncology</i> , 2021, 114, 105164.	1.5	11
3	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	1.5	15
4	Abstract CT153: Correlation of <i>CDKN2A</i> genomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus-unrelated, locally advanced head and neck squamous-cell carcinoma. <i>Cancer Research</i> , 2021, 81, CT153-CT153.	0.9	1
5	358â€¦Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1â€“2 trial. , 2021, 9, A385-A385.		0
6	Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2020, 37, 12.	2.5	5
7	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1295-1305.	10.7	87